Pathological and biological analyzes of angiogenesis on urological cancers

泌尿系统癌症血管生成的病理学和生物学分析

• 批准号: 08457419
• 负责人: KATO Tetsuro
• 金额: $ 1.09万
• 依托单位: Akita University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 1996
• 资助国家: 日本
• 起止时间: 1996 至 1997
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-08457419/
• 关键词: Renal cell carcinoma; VEGF; bFGF; 血管新生因子; 微小血管密度; P53変異; 膀胱癌

Solid tumor growth essentially requires neovascularization regulateted by various angionenic factors. Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) are considered to play an inevitable role in growth of solid tumors, as indicated by immunohistochemical and biogenetic procedure. We investigated the usefulness of serum VEGF and FGF-2 levels in RCC patients as a tumor marker for RCC.Serum levels of VEGF and FGF-2 in peripheral blood samples were analyzed in 40 patients with RCC and 40 noncancerous patients (control) using sandwich enxyme-linked immunoassay (EIA). In 20 RCC patients, serum samples were obtained from bilateral renal veins. Serum VEGF levels were also measured before and 4 weeks after radical nephrectomy in 6 patients, and at the time of diagnosis of diseasem progression in 3.The serum VEGF level in RCC patients were significantly higher than that in the control (207.3(]SY.+-。[)32.9 vs.71.5(]SY.+-。[)9.1pg/ml, p<0.005), while no significant difference was observed in the serum FGF-2 level between RCC patients and the control (14.4(]SY.+-。[)1.9 vs.14.7(]SY.+-。[)3.0 pg/ml). The sensitivity and specificity of serum VEGF at a cut-off level of 100pg/ml, given by ROC curve, were 80.0% and 72.5%.respectively. The serum VEGF level of the tumor-bearing kidneys was higher than that of the contralateral normal kidneys in 17 (85%) of 20 patients. The serum VEGF level significantly correlated with the tumor status such as tumor volume, tumor extent and existence of metastasis. A decreased serum VEGF level was detected in 5 of 6 patients after radical nephrectomy and an increase in all 3 patient with tumor progressions.The present results suggest taht VEGF is secreted by the tumor tissue itself and its serum level could be a candidate marker for RCC which reflects the tumor status better than that of FGF-2.

实体瘤生长基本上需要由各种血管生成因子调节的新血管形成。血管内皮生长因子（VEGF）和碱性成纤维细胞生长因子（FGF-2）在实体瘤的生长过程中起着重要作用。为探讨肾细胞癌患者血清VEGF和FGF-2水平作为肾细胞癌肿瘤标志物的价值，采用酶联免疫法（EIA）检测了40例肾细胞癌患者和40例非癌患者（对照组）外周血VEGF和FGF-2水平。在20例RCC患者中，从双侧肾静脉获得血清样品。6例肾癌患者术前、术后4周及3例肾癌进展时测定血清VEGF水平。肾癌患者血清VEGF水平明显高于对照组（207.3 ± 0.01），差异有统计学意义（P < 0.05）。[）32.9 vs.71.5（]SY. ±. [）9.1pg/ml，p<0.005），而肾细胞癌患者与对照组之间血清FGF-2水平无显著差异（14.4（]SY. ±-. [)1.9 vs.14.7（]SY. ±. [)3.0 pg/ml）。以100 pg/ml为界值，ROC曲线显示VEGF对胃癌的敏感性为80.0%，特异性为72.5%。20例患者中17例（85%）患肾血清VEGF水平高于对侧正常肾。血清VEGF水平与肿瘤体积、肿瘤范围及有无转移密切相关。6例肾癌根治术后血清VEGF水平5例下降，3例肾癌进展患者血清VEGF水平均升高，提示VEGF是肾癌组织自身分泌的，血清VEGF水平可作为肾癌的一项候选指标，其反映肾癌的状态优于FGF-2。

项目成果

佐藤 一成, 加藤 哲郎: "腎細胞癌における腫瘍血管の増生と血管増生因子の相関" 癌と化学療法. 24巻. 389-394 (1997)

Kazunari Sato、Tetsuro Kato：“肾细胞癌中肿瘤血管增殖和血管生长因子的相关性”癌症与化疗，第 24 卷，389-394（1997 年）。

佐藤一成、ほか: "腎細胞癌における腫瘍血管の増生と血管増生因子の相関." 癌と化学寮. 24(4). 389-394 (1997)

Kazunari Sato 等人：“肾细胞癌中肿瘤血管增殖和血管生长因子的相关性”，Cancer to Kagakuryo 24(4) (1997)。

富樫寿文、ほか: "尿路移行上皮癌の組織学的悪性度に対する血管内皮成長因子(VEGF)とp53遺伝子の関わり" 日泌尿会. 88(2). 97(A)- (1997)

Hisafumi Togashi 等人：“血管内皮生长因子 (VEGF) 和 p53 基因与尿路移行细胞癌组织学恶性肿瘤的关系”，日本泌尿学会 88(2)-(1997)。

佐藤一成, 加藤哲郎: "腎細胞癌における腫瘍血管の増生と血管増生因子の相関" 癌と化学療法. 24巻. 389-394 (1997)

Kazunari Sato、Tetsuro Kato：“肾细胞癌中肿瘤血管增殖和血管生长因子的相关性”癌症与化疗，第 24 卷，389-394（1997 年）。

小倉泰伸、ほか: "表在性膀胱癌における血管新生因子の発現と腫瘍血管密度に関する免疫組織化学的検討" 日泌尿会誌. 88(2). 97(A)- (1997)

Yasunobu Ogura 等人：“浅表性膀胱癌中血管生成因子表达和肿瘤血管密度的免疫组织化学研究”日本泌尿学会杂志 88(A)-(1997)。